GMP “Design Space” To Facilitate FDA Quality Initiative Implementation
This article was originally published in The Pink Sheet Daily
“Design Space” is emerging as a pivotal concept in FDA’s effort to integrate its pharmaceutical application review and inspection operations into a new “quality assessment” system. With regulatory flexibility for manufacturing changes in the balance, the agency will be working with industry to refine the concept and its application in drug development and manufacturing.
You may also be interested in...
ICH's quality risk management draft guideline "Q9" provides a common language and systematic approach that will facilitate industry/regulator communications. ICH Q9 is intended to provide a practical toolbox to accompany the pharmaceutical development ("Q8") and newly agreed to quality systems ("Q10") facets of the ICH effort to evolve a more harmonized and flexible quality oversight process.
NDA and ANDA pilot programs will help transform the way CMC information is submitted and reviewed by FDA. Office of Generic Drugs' white paper on "question-based review" follows the introduction of an NDA pilot program in mid-July.